

Delayed anaphylactic reaction to intravenous infusion of ondansetron report of 3 cases

Nesrine BS^{1*}, Haifa R¹, Bouraoui EO², Bechir A¹, Emna B¹, Rabiaa A³, Yosra BY¹, Rawdha S², Salem CB², Houcem H³, Abederrahim K¹ and Zorgati O³

¹Departement of Clinical Hematology, Farhat Hached University Hospita, Sousse, Tunisia

²Departement of pharmacology, Farhat Hached University Hospital, Sousse, Tunisia

³Medical intensive care unit, Sahloul University Hospital, Sousse, Tunisia

Abstract

Ondansetron hydrochloride is a selective 5 hydroxy-tryptamine 3 (5-HT₃) receptor antagonist widely used as an effective antiemetic especially for the prevention of chemotherapy-induced nausea and vomiting caused by highly emetogenic drugs such as Cisplatin.) When its used in combination with corticosteroids these agents result in complete protection from acute-onset emesis is between 70% and 80% of patients so It may be considered as gold standard for this purpose. All 5-HT₃ receptor antagonists have been associated with asymptomatic electrocardiogram changes but anaphylactic shock or hypersensitivity to ondansetron was rarely reported. In this paper, we report 3 cases of delayed anaphylactic reaction to the drug cited above.

Introduction

Ondansetron hydrochloride is a selective 5 hydroxy-tryptamine 3 (5-HT₃) receptor antagonist widely used as an effective antiemetic especially for the prevention of chemotherapy-induced nausea and vomiting [1] caused by highly emetogenic drugs such as Cisplatin. The efficacy of these drugs (ondansetron, tropisetron, granisetron, palonosetron) has been reported in several studies and clinical experience has been that they are well tolerate [2] When its used in combination with corticosteroids these agents result in complete protection from acute-onset emesis is between 70% and 80% of patients so It may be considered as gold standard for this purpose [3]. The most common side effects are headaches, diarrhea, constipation, fever and dizziness [4-6]. All 5-HT₃ receptor antagonists have been associated with asymptomatic electrocardiogram changes but anaphylactic shock or hypersensitivity to ondansetron was rarely reported. In this paper, we report 3 cases of delayed anaphylactic reaction to the drug cited above.

Case 1

A-32- years old woman with no medical history was admitted to our department to undergo an induction course of chemotherapy for newly diagnosed acute myeloblastic leukemia in June 2016. After the first injection of ondansetron on the first day of chemotherapy she immediately became hypotensive with blood I pressure of 80/40 mm Hg. There was no accompanying urticaria, angioedema, or respiratory distress. This episode was rapidly improved with i.v., hydrocortisone, and fluids, after which she became normotensive. The patient continued her chemotherapy without incidents. However after the twentieth dose of ondasetron she claimed of dizziness, breath shortness immediately flowed by deep hypotension (60/30 mmhg), dyspnea (30 cycl/min) and tachycardia (150 bat/min) without skin rash, edema or bronchospasm. Quickly IV fluid, bolus of dexamethasone were administrated but she kept the same symptoms so added 14 bolus of adrenaline (0.1 mg)

followed by continuous infusion of both adrenaline and noradrenaline in the purpose to enhance blood pressure but the patient died in a context of cardio-respiratory arrest despite 20 minutes of resuscitation.

Case 2

A-34-years old woman was scheduled to undergo chemotherapy for newly hyperleucotysis and tumor acute T lymphoblastic leukemia according to Hyper-CVAD chemotherapy which consists of two combinations of drugs (courses A and B) given in an alternating fashion on March 2016. Since then she received two courses (A) of cyclophosphamide, vincristine, dexamethason and doxorubicine and one B courses containing high dose methotrexate, cytarabine arabinoside all containing ondansetron injection to prevent vomiting. All courses were unfolded without incidents. Then she was admitted to have the fourth cycle (B), during the first ondansetron infusion on this cycle she immediately experienced flushing of her face and cutaneous itching followed by shortness of breath with chest pain, severe hypotension and tachycardia. This hypotension was unresponsive to large intravenous fluid and dexamethasone injections (8 mg) therefore she required repeated adrenaline boluses and a noradrenaline infusion in association with adrenaline nebulization. Unfortunately, she developed acute respiratory distress requiring then intubation, 2 hours later the patient died in a context of a cardio-respiratory arrest.

Case 3

A 33 years old female is followed in our department for recently diagnosed of good prognostic acute myeloblastic CBF leukemia.

Correspondence to: Ben Sayed Nesrine, Departement of Clinical Hematology, Farhat Hached University Hospita, Sousse, Tunisia, E-mail: nesrinebensayd@yahoo.fr

Received: February 14, 2017; **Accepted:** March 10, 2017; **Published:** March 13, 2017

Treatment was based on chemotherapy regimen containing cytarabine arbinoside and anthracyclins which is usually associated with ondansetron to prevent chemo-induced vomiting. She received the induction and the first consolidation courses with no further problems and then she was hospitalized for the second consolidation course based on high dose of cytarabine arabinoside, during the first infusion of ondansetron ongoing this cycle she claimed of dizziness, cold sweat then rapidly she became hypotensive (80/40 mmhg) and bradycardiac (45 bt/min) without oedema, skin itching or bronchospasm. The infusion was stopped and IV fluid with dexametason were given but she remains hypotensive so we added a bolus of adrenaline and continuous noradrenaline infusion to enhance blood pressure. Fortunately, she responded to catecholamins and undergo her chemotherapy with no incident. Otherwise she received her third and last consolidation course with no vomiting prophylaxis. To more emphasizaize on this fact we completed investigation with prick test which were negative, no cross-reactivity reaction or intradermo-reaction were not also done because of the severity of the reaction.

Discussion

The main concern of patients receiving anticancer drugs is nausea and emesis because of release of serotonin from the enterochromaffin cells of the small intestine, which may stimulate the vagal afferent pathways through (5-HT₃) receptors and so initiate the vomiting reflex 5HT₃ selective antagonists such as ondansetron, tropisetron, granisetron, palonosetron are generally associated with wide safety margin and widely used in cancer chemotherapy patients and post-surgical patients to prevent nausea and vomiting [4]. Furthermore, the frequency of adverse events with the new compound is lower than that with conventional antiemetic regimens. Life-threatening reactions have been uncommonly reported [5] however, besides the mild side effects such as diarrhea (16%), fever (8%) headache (17%) [6], these drugs also have been reported to cause coronary vasospasm, [1,6], chest pain [7,8] generalized tonic-clonic seizures [4,9] dystonia [10] and allergic reactions that may be fatal [6,11]. This has prompted some authors to suggest that the drug's use should be restricted [12].

In our report the 2 first cases have had a fatal outcome after they developed the anaphylactic reaction knowing that they did receive ondansetron earlier in the previous courses of chemotherapy. They were dead despite the quick management of the incident then we had not the opportunity to practice any test to confirm drug causality but the third case survived the episode and prick test was negative. Keeping in mind the severity of the developed reaction skin test to different dilution of the drug (intra-dermal test) were not practiced as well as no cross activity tests were done also because other 5-HT₃ receptor antagonist were unavailable. The precise mechanism of the adverse reaction to ondansetron is unclear. Chen et al analysed results from the US Federal Drug Administration spontaneous reporting system with respect to ondansetron and were able to find 24 reports describing anaphylactic- anaphylactoid reaction [13].

Anaphylaxis is an acute-onset, potentially fatal, systemic allergic reaction and prior exposure to an antigen is required for IgE dependent anaphylactic reaction [14-15]. Thus, earlier doses have probably led to the sensitization of these patients. It was the 56th dose of ondansetron in the case of Dermir *et al.* that caused anaphylaxis albeit the patient received earlier doses with no adverse reaction [1] same situation on the case of Frigerio C *et al.* [12] as well as for Kossay and kwnk [16].

Many anaphylactic reactions without any usual features of allergy such as itching, flashing, edema or bronchospasm were reported.

Fernando and Broadfoot [17] and Pretti Goyal *et al.* [5] reported a reaction that consisted of marked hypotension without skin rash or bronchospasm, as was the case in our 3 patients.

In the literature, anaphylactic/anaphylactoid reactions induced by ondansetron have been reported in cancer chemotherapy patients. Some authors suggest that anaphylaxis may be class effect [10,11] while some others think it is drug specific effect [12] as ondansetron and tropisetron share indole heterocycle, while granisetron does not have indole ring [18].

While anaphylaxis is IgE mediated, anaphylactoid reactions are non-immune mediated, we did not determine specific IgE levels to the drug in our survived patient despite the fact that skin tests were negatives, given the serious nature of the reaction. Thus, the reaction could have been either anaphylaxis or anaphylactoid, but the latter seems more likely. Gisèle Kanny *et al.* published in 2001 the first case of IgE-mediated hypersensitivity proved by positive immediate intradermal test (IDT) and leukocyte histamine release test (LHRT) results despite the negativity of skin prick tests [19].

Management of the anaphylactic signs and symptoms requires both supportive and preventive approaches [14,15]. The 3 cases received adrenaline, noradrenaline and steroid during the acute phase but unfortunately 2 patients died and the third case continued to have steroid for 5 day after weaning noradreanaline. She was given the remaining cycles of chemotherapy with metoclopramide and had no further other problems occurred.

In the wake of the above evidence, and the increasing availability and off label use of ondansetron and other 5-HT₃ receptor antagonists, we need to be more cautious while using this drug and also to be aware of the various unusual side effects, especially when used in an out-of hospital set-up where prompt treatment of the reaction may not be possible [11].

Conclusion

Ondansetron is an effective antiemetic drug for chemotherapy-induced nausea and vomiting. Rarely, anaphylactic reaction may occur like in ours cases. Nevertheless, in view of life threatening anaphylactic/anaphylactoid reactions developing after i.v. ondansetron those prescribing it or other 5HT₃ antagonists should exercise extreme caution especially in patients with history of hypersensitivity reactions We also caution against off label use of these drugs, especially in out of hospital set up [18]. Otherwise the precise mechanism of the adverse reaction to ondansetron is unclear, but negative skin prick test does not support or nullify IgE mediated mechanism or histamine liberation by mastocytes [13,19].

References

1. Ahmet H, Demir (2010) Anaphylactic Reaction Owing to Ondansetron Administration in a Child With Neuroblastoma and Safe Use of Granisetron: A Case Report. *J Pediatr Hematol Oncol* 32: e341–e342.
2. Jones al, Hills AS, Soukop (1991) Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. *Lancet* 338: 483-487.
3. Ronald AE, Matti AAE, Blower PR (2005) Is there a pharmacological basis for differences in 5-HT₃-receptor antagonist efficacy in refractory patients?. *Cancer Chemother Pharmacol* 56: 231-238.
4. Sharma A, Raina V (2001) Institute Rotary Cancer Hospital. All India Institute of Medical Sciences, Medical Oncology, New Delhi, India, Generalized seizures following ondansetron. *Annals of Oncology* 12: 131-133.
5. Goyal P, Paramesh K, Puranik S, Proctor M, Sanghvi M (2016) Delayed diagnosis of

- anaphylaxis secondary to ondansetron: A case report. *Eur J Anaesthesiol* 33: 140-155.
6. Havrilla PL, Kane GSL, Verrico MM (2009) Coronary vasospasm and atrial fibrillation associated with ondansetron therapy. *Ann Pharmacother* 43: 532-536.
 7. Harold S, Ballard, Bottino G, Bottino J (1992) Ondansetron and chest pain. *The Lancet* 340: 1049-1110.
 8. James BDP (1992) Ondansetron and chest pain. *The Lancet* 340: 1223-1224.
 9. Sargent AL, Deppe SA (1993) Seizure associated with ondansetron. *Clin Pharmacol* 12 : 613-615
 10. Tolan MM, Fuhrman TM, Tsueda K (1999) Lippmann SB Perioperative extrapyramida reactions associated with ondansetron. *Anesthesiology* 90: 340.
 11. Karishma KM, Gogtay NJ, Ainchwar R, Bichile LS (2008) Hypersensitivity to intravenous ondansetron: a case report. *Journal of Medical Case Reports* 2: 274.
 12. Frigerio C, Buchwalder PA, Spertini F (1996) Ondansetron: reasons to be restrictive. *The Lancet* 347: 25.
 13. Chen M, Tanner A, Torres G (1993) Anaphylactoid- anaphylactic reactios associated with ondansetron. *Annl Intern Mes* 119: 862.
 14. Simons FER (2008) Anaphylaxis. *J Allergy Clin Immunol* 121(2 suppl): S402-S407.
 15. Ross AK, Ferrero-Conover D (1998) Anaphylactoid reaction due to administration of ondansetron in a pediatric neurosurgical patient. *Anesth Analg* 87: 779-780.
 16. Kossey JL, Kwok KK (1994) Anaphylactoid reactions associated with ondansetron. *Ann Pharmacother* 28:1029-1030.
 17. Fernando SL, Broadfoot AJ (2009) Ondansetron anaphylaxis: a case report and protocol for skin testing. *Br J Anaesth* 102: 285-286.
 18. Rajesh RV, Salimath S, Janaki TR (2014) A case of anaphylactic/anaphylactoid reaction to ondansetron injection. *International Journal of Recent Trends in Science and Technology* 12: 262-563.
 19. Kanny G, Beaudouin E, Vautrin AM (2001) IgE-mediated allergy to granisetron and safe use of ondansetron. *J Allergy Clin Immunol* 108: 1059-1060.